icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety of Finite 48-week Treatment With the
siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379
in HBeAg Negative Virologically Suppressed Chronic Hepatitis
B Patients: Results from the REEF-2 Study

 
 
  EASL 2022 June 22-26 London
 
Kosh Agarwal,1 Maria Buti,2 Florian van B÷mmel,3 Pietro Lampertico,4 Ewa Janczewska,5 Marc Bourliere,6 Thomas Vanwolleghem,7,8 Oliver Lenz,9 Thierry Verbinnen,9 Thomas N. Kakuda,9 Cristiana Mayer,9 John Jezorwski,9 Maria Beumont,9 Ronald Kalmeijer,9 Michael Biermer,9 Isabelle Lonjon-Domanec9
 
1Institute of Liver Studies, King's College Hospital, London, England; 2Hospital Universitario Valle de Hebrˇn, Barcelona, Spain; 3University Hospital Leipzig, Leipzig, Germany; 4Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy; 5Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland; 6H˘pital Saint Joseph, Marseille, France; 7Antwerp University Hospital (UZA), Edegem, Belgium; 8Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium; 9Janssen Research & Development.

0624221

0624222

0624223

0624224

0624225

0624226

0624227

0624228